Save The Date For Achillion Pharma

(RTTNews) - Achillion Pharmaceuticals Inc. (ACHN), which is slated to report clinical data next week, has gained 7% so far this month.

Achillion Pharma is a clinical-stage biopharmaceutical company developing orally administered, small molecule, Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy.

Paroxysmal Nocturnal Hemoglobinuria, or PNH, is a rare, acquired, blood disorder, leading to life threatening hemolysis. C3 Glomerulopathy is associated with a decline in kidney function over time.

The Company's lead drug candidate is ACH-4471, a first generation oral Factor D inhibitor, under phase II trials in paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

The PNH program consists of two trials - a phase II clinical trial in untreated PNH patients where ACH-4471 is being assessed as a monotherapy, and a phase II trial evaluating ACH-4471 in patients who are inadequately controlled or sub-optimally responding to Soliris, which is a therapy for patients with PNH.

The C3G program consists of three currently recruiting phase II clinical trials -- a 14-day biomarker study, a six-month blinded, placebo-controlled study, and a 12-month open label study.

Also in the pipeline are ACH-5228 and ACH-5548, which are next-generation oral factor D inhibitors currently in phase I clinical trials in healthy volunteers. Both ACH-5228 and ACH-5548 are being developed for C3G, PNH and other Alternative Pathway-mediated diseases.

Near-term Catalysts:

On December 17, the Company is slated to present interim data from its phase II clinical trials of ACH-4471 in PNH and C3G, as well as initial phase I data on its next generation factor D inhibitors ACH-5228 and ACH-5548.

Narrowing loss, ample cash...

For the third quarter ended September 30, 2018, Achillion's net loss narrowed to $15.9 million or $0.12 per share from $19.3 million or $0.14 per share during the same period of 2017.

The Company ended the third quarter of 2018 with cash, cash equivalents, marketable securities, and interest receivable of $283.1 million.

ACHN has traded in a range of $2.33 to $4.34 in the last 1 year. The stock closed Monday's trading at $3.09, down 0.64%.